Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 750

1.

Perceptions of emtricitabine-tenofovir in HIV PrEP.

Kruse L, Stover K, Henderson H.

HIV Clin. 2014 Winter;26(1):1, 4-7. No abstract available.

PMID:
24855688
[PubMed - indexed for MEDLINE]
2.

Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.

Vogler MA, Smeaton LM, Wright RL, Cardoso SW, Sanchez J, Infante R, Moran LE, Godfrey C, Demeter LM, Johnson VA.

J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):542-50. doi: 10.1097/QAI.0000000000000072.

PMID:
24759064
[PubMed - indexed for MEDLINE]
3.

Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.

Mills A, Crofoot G, Ortiz R, Rashbaum B, Towner W, Ward D, Brinson C, Kulkarni R, Garner W, Ebrahimi R, Cao H, Cheng A, Szwarcberg J.

HIV Clin Trials. 2014 Mar-Apr;15(2):51-6. doi: 10.1310/hct1502-51.

PMID:
24710918
[PubMed - indexed for MEDLINE]
4.

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S; ING114915 Study Team.

Lancet. 2014 Jun 28;383(9936):2222-31. doi: 10.1016/S0140-6736(14)60084-2. Epub 2014 Apr 1.

PMID:
24698485
[PubMed - indexed for MEDLINE]
5.

Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.

Kang M, Hollabaugh K, Pham V, Koletar SL, Wu K, Smurzynski M, Aberg JA.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):172-80. doi: 10.1097/QAI.0000000000000149.

PMID:
24694927
[PubMed - indexed for MEDLINE]
6.

Single-tablet, once-daily treatment regimens for HIV.

Sawyer JR, Ma Q, Hsiao CB.

Lancet Infect Dis. 2014 Apr;14(4):265-7. doi: 10.1016/S1473-3099(14)70026-X. No abstract available. Erratum in: Lancet Infect Dis. 2014 Jun;14(6):448.

PMID:
24670622
[PubMed - indexed for MEDLINE]
7.

Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.

Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, Elion RA, Vanveggel S, Stevens M, Rimsky L, Thorpe D, Bosse M, White K, Zhong L, DeMorin J, Chuck SK.

AIDS Patient Care STDS. 2014 Apr;28(4):168-75. doi: 10.1089/apc.2013.0310. Epub 2014 Mar 24.

PMID:
24660840
[PubMed - indexed for MEDLINE]
8.

Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).

Shaffer D, Hughes MD, Sawe F, Bao Y, Moses A, Hogg E, Lockman S, Currier J.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):155-63. doi: 10.1097/QAI.0000000000000131.

PMID:
24562349
[PubMed - indexed for MEDLINE]
9.

Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).

Porter DP, Kulkarni R, Fralich T, Miller MD, White KL.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):318-26. doi: 10.1097/QAI.0000000000000017.

PMID:
24525469
[PubMed - indexed for MEDLINE]
10.

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.

ENCORE1 Study Group, Puls R, Amin J, Losso M, Phanuphak P, Nwizu C, Orrell C, Young B, Shahar E, Wolff M, Gazzard B, Read T, Hill A, Cooper DA, Emery S.

Lancet. 2014 Apr 26;383(9927):1474-82. doi: 10.1016/S0140-6736(13)62187-X. Epub 2014 Feb 10. Erratum in: Lancet. 2014 Apr 26;383(9927):1464.

PMID:
24522178
[PubMed - indexed for MEDLINE]
11.

Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.

Calza L, Vanino E, Salvadori C, Manfredi R, Colangeli V, Cascavilla A, Di Bari MA, Motta R, Viale P.

HIV Clin Trials. 2014 Jan-Feb;15(1):1-13. doi: 10.1310/hct1501-1.

PMID:
24518210
[PubMed - indexed for MEDLINE]
12.

Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.

Kim HN, Rodriguez CV, Van Rompaey S, Eron JJ, Thio CL, Crane HM, Overton ET, Saag MS, Martin J, Geng E, Mugavero M, Rodriguez B, Mathews WC, Boswell S, Moore R, Kitahata MM; Centers for AIDS Research Network of Integrated Clinical Systems.

J Acquir Immune Defic Syndr. 2014 May 1;66(1):96-101. doi: 10.1097/QAI.0000000000000126.

PMID:
24500175
[PubMed - indexed for MEDLINE]
13.

[Integrase inhibitors - new challenges for the treatment of HIV-1 infections].

Stock I.

Med Monatsschr Pharm. 2013 Dec;36(12):448-59; quiz 461-2. Review. German.

PMID:
24450269
[PubMed - indexed for MEDLINE]
14.

Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.

Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, Mujugira A, Tappero J, Kahle EM, Thomas KK, Baeten JM; Partners PrEP Study Team.

AIDS. 2013 Aug 24;27(13):2155-60. doi: 10.1097/QAD.0b013e3283629037.

PMID:
24384592
[PubMed - indexed for MEDLINE]
15.

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.

Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Tebas P, Melbourne K, Ha B, Jahed NC, McComsey GA.

AIDS. 2013 Aug 24;27(13):2069-79. doi: 10.1097/QAD.0b013e328361d25d.

PMID:
24384588
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Emtricitabine/tenofovir (Truvada) for HIV prophylaxis.

Coutinho B, Prasad R.

Am Fam Physician. 2013 Oct 15;88(8):535-40. Review. No abstract available.

PMID:
24364575
[PubMed - indexed for MEDLINE]
17.

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

Clumeck N, Molina JM, Henry K, Gathe J, Rockstroh JK, DeJesus E, Wei X, White K, Fordyce MW, Rhee MS, Szwarcberg J; GS-236-0103 Study Team.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e121-4. doi: 10.1097/QAI.0000000000000089. No abstract available.

PMID:
24346640
[PubMed - indexed for MEDLINE]
18.

Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.

Grant PM, Tierney C, Budhathoki C, Daar ES, Sax PE, Collier AC, Fischl MA, Zolopa AR, Balamane M, Katzenstein D.

HIV Clin Trials. 2013 Nov-Dec;14(6):284-91. doi: 10.1310/hct1406-284.

PMID:
24334181
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.

[No authors listed]

Prescrire Int. 2013 Oct;22(142):233-5.

PMID:
24298581
[PubMed - indexed for MEDLINE]
20.

Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.

Gupta SK, Mi D, Moe SM, Dubé MP, Liu Z.

J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):279-83.

PMID:
24278992
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk